

Vladimir Tesar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/948529/publications.pdf>

Version: 2024-02-01

226
papers

25,928
citations

23567
58
h-index

6836
155
g-index

235
all docs

235
docs citations

235
times ranked

17272
citing authors

#	ARTICLE	IF	CITATIONS
1	CZecking heart failure in patients with advanced chronic kidney disease (Czech HF-CKD): Study protocol. <i>Journal of Vascular Access</i> , 2024, 25, 294-302.	0.9	1
2	The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 551-561.	0.7	10
3	Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1099-1108.	0.7	24
4	Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 89-98.	1.9	0
5	Granulomatosis with polyangiitis mimicking cancer: a diagnostic dilemma. <i>Journal of Nephrology</i> , 2022, 35, 675-678.	2.0	0
6	Vancomycin pharmacokinetics in patients treated with intermittent haemodialysis based on therapeutic drug monitoring. <i>Journal of Chemotherapy</i> , 2022, 34, 149-156.	1.5	3
7	Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry. <i>American Journal of Kidney Diseases</i> , 2022, 79, 635-645.	1.9	3
8	The management of membranous nephropathy—an update. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1033-1042.	0.7	7
9	SGLT2 inhibitors in non-diabetic kidney disease. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 105-107.	1.4	6
10	Indication for corticosteroids in IgA nephropathy: validation in the European VALIGA cohort of a treatment score based on the Oxford classification. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1195-1197.	0.7	7
11	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 393-399.	5.6	71
12	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 400-406.	5.6	62
13	Extrarenal complications of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) and their impact on the outcome of the patients. <i>Journal of Nephrology</i> , 2022, 35, 1065-1068.	2.0	1
14	Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 829-838.	6.1	23
15	Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3317.	4.1	15
16	Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis as a Complication of Home Parenteral Nutrition. <i>Case Reports in Nephrology and Dialysis</i> , 2022, 12, 22-30.	0.6	1
17	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1400-1410.	0.7	21
18	Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis. <i>Kidney Medicine</i> , 2022, 4, 100457.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Early Identification of CKD – A Scoping Review of the Global Populations. <i>Kidney International Reports</i> , 2022, 7, 1341-1353.	0.8	9
20	Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2190-2200.	0.7	11
21	Analysis of microRNAs in Small Urinary Extracellular Vesicles and Their Potential Roles in Pathogenesis of Renal ANCA-Associated Vasculitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4344.	4.1	4
22	Dosing of Aminoglycosides in Chronic Kidney Disease and End-Stage Renal Disease Patients Treated with Intermittent Hemodialysis. <i>Kidney and Blood Pressure Research</i> , 2022, 47, 448-458.	2.0	2
23	New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. <i>Journal of Clinical Medicine</i> , 2022, 11, 2810.	2.4	15
24	The switch from proteasome to immunoproteasome is increased in circulating cells of patients with fast progressive immunoglobulin A nephropathy and associated with defective CD46 expression. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1389-1398.	0.7	4
25	Mass spectrometry-based proteomic exploration of the small urinary extracellular vesicles in ANCA-associated vasculitis in comparison with total urine. <i>Journal of Proteomics</i> , 2021, 233, 104067.	2.4	12
26	Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 79-87.	4.5	18
27	Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy. <i>Kidney International</i> , 2021, 99, 1179-1188.	5.2	47
28	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 671-685.	5.2	24
29	Nephrology in the Czech Republic. , 2021, , 499-509.		0
30	Avacopan for the Treatment of ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2021, 384, 599-609.	27.0	461
31	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	1.9	20
32	Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy. <i>Frontiers in Immunology</i> , 2021, 12, 593288.	4.8	24
33	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1160-1168.	0.7	38
34	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 315-325.	1.9	62
35	Hemodialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 326-335.e1.	1.9	24
36	The effect of high-flow arteriovenous fistulas on systemic haemodynamics and brain oxygenation. <i>ESC Heart Failure</i> , 2021, 8, 2165-2171.	3.1	16

#	ARTICLE	IF	CITATIONS
37	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.8	39
38	COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1758-1760.	0.7	11
39	Lupus nephritis and ANCA-associated vasculitis: towards precision medicine?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 37-43.	0.7	1
40	Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. <i>BMJ Open</i> , 2021, 11, e047245.	1.9	25
41	Reduction of arteriovenous access blood flow leads to biventricular unloading in haemodialysis patients. <i>International Journal of Cardiology</i> , 2021, 334, 148-153.	1.7	12
42	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. <i>Kidney International Reports</i> , 2021, 6, 2903-2907.	0.8	8
43	Outcome of 313 Czech Patients With IgA Nephropathy After Renal Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 726215.	4.8	9
44	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	5.2	782
45	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, 753-779.	5.2	325
46	Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease. <i>Advances in Clinical Chemistry</i> , 2021, 105, 141-212.	3.7	17
47	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 23-35.	2.9	10
48	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 42-52.	0.7	36
49	Plasma exchange in ANCA-associated vasculitis: the pro position. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 227-231.	0.7	12
50	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 159-167.	0.7	9
51	Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 436-447.	6.1	34
52	Chronic kidney disease and pregnancy outcomes. <i>Scientific Reports</i> , 2021, 11, 21299.	3.3	7
53	Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury. <i>Journal of Nephrology</i> , 2021, 34, 1263-1270.	2.0	3
54	Assessing the impact of screening, early identification and intervention programmes for chronic kidney disease: protocol for a scoping review. <i>BMJ Open</i> , 2021, 11, e053857.	1.9	3

#	ARTICLE	IF	CITATIONS
55	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrology Dialysis Transplantation, 2020, 35, 1002-1009.	0.7	66
56	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. Journal of Rheumatology, 2020, 47, 580-588.	2.0	5
57	Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy?. Journal of Nephrology, 2020, 33, 307-316.	2.0	14
58	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. Autoimmunity Reviews, 2020, 19, 102671.	5.8	37
59	Emerging Modes of Treatment of IgA Nephropathy. International Journal of Molecular Sciences, 2020, 21, 9064.	4.1	21
60	Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1103-1111.	4.5	47
61	Englishâ€“Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?. Kidney International, 2020, 98, 1352-1353.	5.2	15
62	MO041URINE PROTEOMICS FOR PREDICTION OF DISEASE PROGRESSION IN PATIENTS WITH IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	7
63	Why Target the Gut to Treat IgA Nephropathy?. Kidney International Reports, 2020, 5, 1620-1624.	0.8	37
64	Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1519-1521.	4.5	6
65	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	12.8	120
66	2019 Update of the Joint European League Against Rheumatism and European Renal Associationâ€“European Dialysis and Transplant Association (EULAR/ERAâ€“EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases, 2020, 79, 713-723.	0.9	463
67	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 1243-1249.	0.9	93
68	Framework for establishing integrated kidney care programs in low- and middle-income countries. Kidney International Supplements, 2020, 10, e19-e23.	14.2	24
69	Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney International Supplements, 2020, 10, e63-e71.	14.2	23
70	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Perspectives. Kidney and Blood Pressure Research, 2020, 45, 157-165.	2.0	9
71	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. New England Journal of Medicine, 2020, 382, 622-631.	27.0	465
72	Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. Nephrology Dialysis Transplantation, 2020, 35, 920-925.	0.7	14

#	ARTICLE	IF	CITATIONS
73	Pulmonaryâ€renal syndrome. Vnitřni Lekarství, 2020, 66, e20-e25.	0.2	0
74	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrology Dialysis Transplantation, 2019, 34, 301-308.	0.7	20
75	Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry. American Journal of Kidney Diseases, 2019, 73, 184-193.	1.9	18
76	Nephrology in the Eastern and Central European region: challenges and opportunities. Kidney International, 2019, 96, 287-290.	5.2	15
77	SP174DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF A PANEL OF SERUM AND URINARY BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
78	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ: British Medical Journal, 2019, 367, l5873.	2.3	131
79	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	12.8	160
80	185.â€fGENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. Rheumatology, 2019, 58, .	1.9	0
81	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	5.6	82
82	118.â€fVALIDATION OF THE RENAL RISK SCORE FOR ANCA-ASSOCIATED GLOMERULONEPHRITIS. Rheumatology, 2019, 58, .	1.9	0
83	Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal. Kidney and Blood Pressure Research, 2019, 44, 298-330.	2.0	80
84	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	5.2	13
85	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	13.7	408
86	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 736-745.	0.9	1,265
87	Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression. PLoS ONE, 2019, 14, e0212254.	2.5	29
88	FRIO193â€...2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
89	FRIO192â€...A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
90	Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney and Blood Pressure Research, 2019, 44, 1493-1505.	2.0	3

#	ARTICLE	IF	CITATIONS
91	Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 210-213.	1.1	6
92	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. <i>Arthritis and Rheumatology</i> , 2019, 71, 411-419.	5.6	45
93	Assessment of renal function before contrast media injection: right decisions based on inaccurate estimates. <i>European Radiology</i> , 2019, 29, 3192-3199.	4.5	2
94	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.	0.9	165
95	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	5.2	198
96	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	5.2	135
97	Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 587-596.	0.7	19
98	Cardiorenal interactions. <i>Cor Et Vasa</i> , 2018, 60, e144-e147.	0.1	1
99	Management of Elderly Patients with Rapidly Progressive Glomerulonephritis. <i>Blood Purification</i> , 2018, 45, 213-217.	1.8	2
100	Avacopan in the treatment of ANCA-associated vasculitis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 491-496.	4.1	28
101	Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 329-349.	2.0	10
102	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	5.2	32
103	FP275A BIOMARKER OF COLLAGEN TYPE III DEGRADATION DECREASES WITH INCREASING FIBROSIS IN THE KIDNEY OF PATIENTS WITH IgA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i124-i124.	0.7	1
104	Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis. <i>American Journal of Nephrology</i> , 2018, 48, 465-471.	3.1	13
105	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2745-2754.	6.1	128
106	SP035 THE ROLE OF S100 PROTEINS AND MATRIX METALLOPROTEINASE AND THEIR INHIBITORS IN THE PATHOGENESIS OF LUPUS NEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i357-i358.	0.7	0
107	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 1039-1049.	0.8	41
108	Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 989-996.	3.1	12

#	ARTICLE	IF	CITATIONS
109	Mutational screening of inverted formin 2 in adult-onset focal segmental glomerulosclerosis or minimal change patients from the Czech Republic. BMC Medical Genetics, 2018, 19, 147.	2.1	10
110	Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrology Dialysis Transplantation, 2017, 32, gfw070.	0.7	103
111	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology: JASN, 2017, 28, 2756-2767.	6.1	448
112	Understanding Histopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 711-712.	4.5	6
113	Belimumab in the management of systemic lupus erythematosus – an update. Expert Opinion on Biological Therapy, 2017, 17, 901-908.	3.1	12
114	Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney International, 2017, 92, 693-702.	5.2	154
115	Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet, The, 2017, 389, 2117-2127.	13.7	278
116	Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis. Kidney and Blood Pressure Research, 2017, 42, 509-518.	2.0	3
117	Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2017, 377, 1930-1942.	27.0	420
118	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	3.8	23
119	Immunosuppressive Treatment in C3 Glomerulopathy: Time to Reconsider Our Approach. American Journal of Nephrology, 2017, 46, 93-95.	3.1	4
120	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1684-1687.e10.	2.9	22
121	Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatric Nephrology, 2017, 32, 139-150.	1.7	71
122	NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients. Inflammation Research, 2017, 66, 369-378.	4.0	23
123	Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 3404-3413.	6.1	60
124	Tissue ischemia worsens during hemodialysis in end-stage renal disease patients. Journal of Vascular Access, 2017, 18, 47-51.	0.9	39
125	Gliflozins slow down the progression of diabetic kidney disease. Vnitřní Lekarství, 2017, 63, 723-727.	0.2	0
126	Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study. Disease Markers, 2016, 2016, 1-9.	1.3	21

#	ARTICLE	IF	CITATIONS
127	MO040ASSOCIATION OF A TNFSF13B (BAFF) REGULATORY REGION SINGLE NUCLEOTIDE POLYMORPHISMS WITH RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2016, 31, i45-i46.	0.7	0
128	MP170CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS TREATED WITH PLASMA EXCHANGE IN A SINGLE CENTRE. Nephrology Dialysis Transplantation, 2016, 31, i397-i397.	0.7	0
129	MP207SERUM MATRIX METALLOPROTEINASES MMP-2 AND MMP-9 AND METALLOPROTEINASE TISSUE INHIBITORS TIMP-1 AND TIMP-2 IN PATIENTS WITH ACUTE KIDNEY INJURY. Nephrology Dialysis Transplantation, 2016, 31, i409-i409.	0.7	0
130	Urine sCD163: a window onto glomerular inflammation. Nephrology Dialysis Transplantation, 2016, 31, 1970-1972.	0.7	3
131	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.9	940
132	Markers for the progression of IgA nephropathy. Journal of Nephrology, 2016, 29, 535-541.	2.0	66
133	Moderator's view: Cyclophosphamide in lupus nephritis. Nephrology Dialysis Transplantation, 2016, 31, 1058-1061.	0.7	1
134	Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study. Arthritis Research and Therapy, 2016, 18, 168.	3.5	14
135	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	1.9	57
136	Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy. Nephron, 2016, 132, 15-24.	1.8	60
137	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	1.9	19
138	Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications. American Journal of Nephrology, 2016, 43, 1-19.	3.1	106
139	Rituximab for treatment of severe renal disease in ANCA associated vasculitis. Journal of Nephrology, 2016, 29, 195-201.	2.0	33
140	Lupus nephritis management guidelines compared. Nephrology Dialysis Transplantation, 2016, 31, 904-913.	0.7	97
141	HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2016, 160, 1-10.	0.6	24
142	Lupus Nephritis: A Different Disease in European Patients?. Kidney Diseases (Basel, Switzerland), 2015, 1, 110-118.	2.5	27
143	FP124MATRIX METALLOPROTEINASES (MMP-2, 3, 7, 9) AND THEIR TISSUE INHIBITORS (TIMP-1, 2) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Nephrology Dialysis Transplantation, 2015, 30, iii108-iii108.	0.7	0
144	Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease. BioMed Research International, 2015, 2015, 1-8.	1.9	35

#	ARTICLE	IF	CITATIONS
145	Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?. Nephrology Dialysis Transplantation, 2015, 30, 1088-1090.	0.7	3
146	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Associationâ€“European Dialysis and Transplant Association Registry. American Journal of Kidney Diseases, 2015, 66, 613-620.	1.9	52
147	Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab. American Journal of Nephrology, 2015, 41, 296-301.	3.1	39
148	Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. Arthritis Research and Therapy, 2015, 17, 371.	3.5	20
149	Corticosteroids in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 2248-2258.	6.1	187
150	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Annals of the Rheumatic Diseases, 2015, 74, 1178-1182.	0.9	217
151	Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis â€“ still of value for our patients?. Expert Opinion on Pharmacotherapy, 2015, 16, 1683-1702.	1.8	5
152	Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1128-1135.	4.5	75
153	A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with TAcrolimusâ€“Rituximab versus steroids plus cyclophosphamide in patients with primary MEbranous Nephropathy: the STARMEN study. CKJ: Clinical Kidney Journal, 2015, 8, 503-510.	2.9	47
154	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes and Endocrinology, the, 2015, 3, 687-696.	11.4	221
155	Limitations of Standard Immunosuppressive Treatment in ANCA-Associated Vasculitis and Lupus Nephritis. Nephron Clinical Practice, 2015, 128, 205-215.	2.3	19
156	Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994â€“2011. Journal of Nephrology, 2015, 28, 39-49.	2.0	55
157	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrology Dialysis Transplantation, 2014, 29, iv26-iv32.	0.7	11
158	Repeat protocol renal biopsy in ANCA-associated renal vasculitis. Nephrology Dialysis Transplantation, 2014, 29, 1728-1732.	0.7	31
159	Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2014, 30 Suppl 1, i159-63.	0.7	13
160	IgA Nephropathy in Czech Patients - Are We Able Reliably Predict the Outcome?. Kidney and Blood Pressure Research, 2014, 39, 555-562.	2.0	9
161	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2014, 64, 40-48.	1.9	55
162	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney International, 2014, 86, 828-836.	5.2	373

#	ARTICLE	IF	CITATIONS
163	Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients. <i>Atherosclerosis</i> , 2014, 236, 263-269.	0.8	12
164	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. <i>Nature Genetics</i> , 2014, 46, 1187-1196.	21.4	505
165	Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1571-1576.	4.5	53
166	Cys327Cys polymorphism of the PAPP-A gene (pregnancy associated plasma protein A) is related to mortality of long term hemodialysis patients. <i>Clinical Biochemistry</i> , 2014, 47, 578-583.	1.9	3
167	Addition of ETA receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats. <i>Life Sciences</i> , 2014, 118, 297-305.	4.3	19
168	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919.	4.5	19
169	ANCA-Associated Renal Vasculitis - An Update. <i>Contributions To Nephrology</i> , 2013, 181, 216-228.	1.1	3
170	Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1839-1844.	0.7	177
171	Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study. <i>BMC Nephrology</i> , 2013, 14, 245.	1.8	19
172	The coincidence of IgA nephropathy and Fabry disease. <i>BMC Nephrology</i> , 2013, 14, 6.	1.8	15
173	Rare transformation in repeat renal biopsies suggests a different pathogenesis of segmental and global lesions in proliferative lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2929-2932.	0.7	4
174	The retrospective analysis of 343 Czech patients with IgA nephropathy--one centre experience. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1492-1498.	0.7	29
175	Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) - intra- and inter-individual variability in chronic hemodialysis patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 296-303.	1.2	1
176	Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. <i>PLoS Genetics</i> , 2012, 8, e1002765.	3.5	301
177	Pregnancy-associated plasma protein A: spotlight on kidney diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1183-90.	2.3	9
178	EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 <i>Clinical Biochemistry</i> , 2012, 45, 556-560.	1.9	12
179	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
180	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 955-960.	0.9	348

#	ARTICLE	IF	CITATIONS
181	Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine, 2012, 367, 214-223.	27.0	820
182	Pregnancy-Associated Plasma Protein A as an Independent Mortality Predictor in Long-Term Hemodialysis Patients. Kidney and Blood Pressure Research, 2012, 35, 192-201.	2.0	19
183	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Annals of the Rheumatic Diseases, 2011, 70, 80-85.	0.9	47
184	Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. New England Journal of Medicine, 2011, 365, 1886-1895.	27.0	544
185	Treatment of proliferative lupus nephritis: a slowly changing landscape. Nature Reviews Nephrology, 2011, 7, 96-109.	9.6	33
186	Serum S100A12 (EN-RAGE) Levels in Patients with Decreased Renal Function and Subclinical Chronic Inflammatory Disease. Kidney and Blood Pressure Research, 2011, 34, 457-464.	2.0	14
187	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	13.7	2,087
188	Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression. Nephrology Dialysis Transplantation, 2011, 26, 573-579.	0.7	15
189	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology, 2011, 50, 899-905.	1.9	89
190	Associations of Serum Levels of Advanced Glycation end Products with Nutrition Markers and Anemia in Patients with Chronic Kidney Disease. Renal Failure, 2011, 33, 131-137.	2.1	16
191	Lower Retinol Levels as an Independent Predictor of Mortality in Long-term Hemodialysis Patients: A Prospective Observational Cohort Study. American Journal of Kidney Diseases, 2010, 56, 513-521.	1.9	28
192	Genetic Predisposition to Advanced Glycation End Products Toxicity Is Related to Prognosis of Chronic Hemodialysis Patients. Kidney and Blood Pressure Research, 2010, 33, 30-36.	2.0	16
193	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. JAMA - Journal of the American Medical Association, 2010, 304, 2381.	7.4	524
194	Peritoneal dialysis in the elderly—is its underutilization justified?. Nephrology Dialysis Transplantation, 2010, 25, 3473-3476.	0.7	3
195	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine, 2010, 363, 211-220.	27.0	1,471
196	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.9	139
197	Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1103-1112.	6.1	923
198	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2009, 68, 1125-1130.	0.9	72

#	ARTICLE	IF	CITATIONS
199	Intracellular Cytokine Production in ANCA-associated Vasculitis: Low Levels of Interleukin-10 in Remission Are Associated with a Higher Relapse Rate in the Long-term Follow-up. Archives of Medical Research, 2009, 40, 276-284.	3.3	25
200	Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Annals of Internal Medicine, 2009, 150, 670.	3.9	790
201	Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine, 2009, 360, 1395-1407.	27.0	1,781
202	Mycophenolate Mofetil in Low Doses Stabilizes and Improves Antineutrophil Cytoplasmic Antibody-associated Vasculitis and Lupus Nephritis. Archives of Medical Research, 2008, 39, 115-119.	3.3	8
203	Recent Progress in the Pathogenesis of Nephrotic Proteinuria. Critical Reviews in Clinical Laboratory Sciences, 2008, 45, 139-220.	6.1	18
204	Outcome of Thirty Patients with ANCA-Associated Renal Vasculitis Admitted to the Intensive Care Unit. Renal Failure, 2008, 30, 890-895.	2.1	25
205	Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2007, 22, 2020-2026.	0.7	68
206	Does Renal Function Influence Plasma Levels of Advanced Glycation and Oxidation Protein Products in Patients with Chronic Rheumatic Diseases Complicated by Secondary Amyloidosis?. Kidney and Blood Pressure Research, 2007, 30, 1-7.	2.0	8
207	Biosimilars and Renal Health Care in the Countries of Central and Eastern Europe. Kidney and Blood Pressure Research, 2007, 30, 2-5.	2.0	1
208	Resting energy expenditure and thermal balance during isothermic and thermoneutral haemodialysis heat production does not explain increased body temperature during haemodialysis. Nephrology Dialysis Transplantation, 2007, 22, 3553-3560.	0.7	16
209	Effect of Hemodiafiltration on Pregnancy-Associated Plasma Protein A (PAPP-A) and Related Parameters. Renal Failure, 2006, 28, 715-721.	2.1	9
210	Soluble Receptor for Advanced Glycation End Products in Patients With Decreased Renal Function. American Journal of Kidney Diseases, 2006, 47, 406-411.	1.9	146
211	Unusual manifestation of AL amyloidosis-stenosis of inferior vena cava. Nephrology Dialysis Transplantation, 2006, 21, 1430-1433.	0.7	1
212	High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrology Dialysis Transplantation, 2006, 21, 3115-3121.	0.7	164
213	A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrology Dialysis Transplantation, 2006, 22, 179-186.	0.7	64
214	Laudatio to Professor Otto Schöck on the Occasion of His 80th Birthday. Kidney and Blood Pressure Research, 2006, 29, 327-328.	2.0	0
215	Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 579, 37-46.	1.0	167
216	Secondary Membranous Nephropathy-One Center Experience. Renal Failure, 2005, 27, 397-402.	2.1	4

#	ARTICLE	IF	CITATIONS
217	Immunotactoid glomerulonephritis as a cause of acute renal failure. Nephrology Dialysis Transplantation, 2004, 19, 1016-1017.	0.7	4
218	The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. Nephrology Dialysis Transplantation, 2004, 19, 3040-3049.	0.7	187
219	Rokitansky and his first description of polyarteritis nodosa. Journal of Nephrology, 2004, 17, 172-4.	2.0	14
220	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. New England Journal of Medicine, 2003, 349, 36-44.	27.0	1,239
221	Glycooxidation and inflammation in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 2577-2581.	0.7	47
222	Soluble cytokine receptors in renal vasculitis and lupus nephritis. Medical Science Monitor, 2002, 8, BR24-9.	1.1	11
223	Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome. Medical Science Monitor, 2002, 8, BR69-74.	1.1	5
224	LONG TERM TREATMENT OF IgA NEPHROPATHY WITH CYCLOSPORINE A. Renal Failure, 2000, 22, 55-62.	2.1	7
225	The Influence of Pefloxacin on Experimental Adriamycin-Induced Nephrotic Syndrome in Rats. Renal Failure, 1996, 18, 195-199.	2.1	1
226	Complement Inhibition in ANCA-Associated Vasculitis. Frontiers in Immunology, 0, 13, .	4.8	11